LY2140023

Overview

LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039. Most currently approved antipsychotic medications work by affecting the neurotransmitters dopamine or serotonin. For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed. Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.

Indication

Investigated for use/treatment in psychosis and schizophrenia and schizoaffective disorders.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Glutamate Reducing Interventions in Schizophrenia	2017/10/25	NCT03321617	Phase 1	Completed	New York State Psychiatric Institute
Study of Pomaglumetad and Methamphetamine	2017/04/10	NCT03106571	Phase 1	Terminated	University of California, Los Angeles
A Study of LY2140023 in Healthy Participants	2012/08/07	NCT01659177	Phase 1	Withdrawn	Denovo Biopharma LLC
A Study of LY2140023 in Healthy Participants	2012/07/11	NCT01637142	Phase 1	Completed	Denovo Biopharma LLC
A Study of LY2140023 in Healthy Participants	2012/05/31	NCT01609218	Phase 1	Completed	Denovo Biopharma LLC
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia	2012/05/25	NCT01606436	Phase 1	Completed	Denovo Biopharma LLC
A Study of LY2140023 in Healthy Males and Females	2012/05/04	NCT01591330	Phase 1	Completed	Denovo Biopharma LLC
A Study of LY2979165 and LY2140023 in Healthy Volunteers	2012/02/01	NCT01524237	Phase 1	Completed	Eli Lilly and Company
A Long-Term Study in Schizophrenia	2011/12/07	NCT01487083	Phase 3	Terminated	Eli Lilly and Company
A Study of LY2140023 in Hepatically-Impaired Participants	2011/11/21	NCT01475136	Phase 1	Completed	Denovo Biopharma LLC

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access